infectious-diseases-2018-posters-abstracts

25 / 35

Infectious Diseases 2018 Journal of Prevention and Infection Control
ISSN: 2471-9668 Page 64
June 07-08, 2018
London, UK
8th Edition of International Conference on
Infectious Diseases
Statement of theProblem: Bacterial resistant is increasing rapidly.
Antibiotic resistance is a global public health problem, more
dominant in the developing countries. This study was conducted
to analyze the annual increase in the antibiotic resistant.
Methodology&Theoretical Orientation: In this comparative study,
the antibiotic susceptibility reports of hospital located in Karachi
was analyzed. The data is openly available. Two antibiogram of
June-Nov 2011 and June-Nov 2012 were analyzed. The annual
incrementinbacterialresistantagainstthreestrainsi.eEscherichia
Coli, Klebsiella and Enterobacter species was determined.
Findings: Escherichia Coli developed additional resistant against
amikacin (13%), amoxicillin/clavulanic acid and ceftriaxone
(2% each), aztreonam (5%), piperacillin/tazobactam (3%),
ceftazidime (14%), co-trimoxazole and gentamicin (7% each) and
cefoperazone/sulbactam (17%) in one year. Similarly ceftriaxone,
ceftazidime, cefepime, co-trimoxazole and gentamycin (44%
each), aztreonam and amikacin (41% each), ampicillin (34%)
amoxicillin/clavulanic acid (31%), piperacillin/tazobactum (29%)
and cefoperazone/sulbactam (24%) lost its potency against
Klebsiella species. Similarly Enterobacter species became
more resistant to ampicillin (40%), amoxicillin/clavulanic acid
and ceftazidime (36% each), cefepime (34%), aztreonam and
ceftriaxone (32% each), ciprofloxacin (28%) and gentamycin
(27%). While all three strains have developed a least resistant
against polymyxin-B.
Conclusion & Significance: The annual increment in bacterial
resistant shows a pan drug resistant in Pakistan. This study
recommends a conscious use of antibiotics.
Development and pattern of antibiotic resistant: a comparative
study from Pakistan
Muhammad Majid Aziz and Yu Fang
Xi’an Jiaotong University, China
J Prev Infect Cntrol 2018, Volume 4
DOI: 10.21767/2471-8084-C1-003